10813839

PTO/SB/08s (08-03)
Approved for use through 97/31/2006, 0NE 0851-0231
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

Application Number

	, de la constante de la consta		10010000	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Filing Date		2004-03-31	
	First Named Inventor	Hugh	Hugh B. Svendsen et al.	
	Art Unit		2132	
	Examiner Name	Gilbe	erto Barron, Jr.	
	Attorney Docket Numb	er	1104-062	

		· ·			U.S.I	PATENTS			Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue [Date	Name of Pate of cited Docu	entee or Applicant iment	Releva	Columns,Lines where ant Passages or Relevan s Appear
	1	7043644	B2	2006-0	5-09	DeBruine			
If you wis	h to a	ı dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add
			U.S.P	ATENT	APPLK	CATION PUBL	LICATIONS		Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant of cited Document		Releva	Columns,Lines where ant Passages or Relevan s Appear
	1	20030112823	A1	2003-0	6-19	Collins et al.			
	2	20040162871	A1	2004-0	8-19	Pabla et al.			
	3	20030105812	A1	2003-0	6-05	Flowers, Jr. et	tal.		
	4	20030084162	A1	2003-0	5-01	Johnson et al.			
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	blease click the Ad	d buttor	Add
				FOREIG	GN PAT	ENT DOCUM	ENTS		Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear

	Application Number		10813839	
NEODWATION DIGGS COURT	Filing Date		2004-03-31	
NFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Hugh	B. Svendsen et al.	
Not for submission under 37 CFR 1.99)	Art Unit		2132	
Not for Submission under or or it is say	Examiner Name	Gilbe	rto Barron, Jr.	
	Attorney Docket Numb	er	1104-062	

	1									
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
	NON-PATENT LITERATURE DOCUMENTS Remove									
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Τs			
	1									
If you wish to add additional non-patent literature document citation information please click the Add button Add										
EXAMINER SIGNATURE										
Examiner	Examiner Signature Date Considered									

See for Codes of USPTO Platent Documents at year, LISPTO, GOV or MPEP 901.04. * Enter office and assess the document, by the to-elect code (VIPO Standard STI), 3.* *Pragainese platent convented, the noticeable or be parent for early or the Engerer mater processor the senior instruct for platent document. **
**Kind of document by the appropriate symbols as indicated on the document under WIPO Standard STI,16 if possible. **
*Applicant is to place a check mark here fireful language standards in standard.**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10813839		
Filing Date		2004-03-31		
First Named Inventor Hugh		B. Svendsen et al		
Art Unit		2132		
Examiner Name	Gilber	rto Barron, Jr.		
Attorney Docket Numb	er	1104-062		

CERTIFICATION STATEMENT

Please see	37	CFR :	1 97	and :	1 98	to make	the	appropriate	selection(s):	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information siclosure statement. See 37 CFR 197(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Benjamin S. Withrow/	Date (YYYY-MM-DD)	2006-08-08
Name/Print	Benjamin S. Withrow	Registration Number	40876

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 GA 37 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandriu, V.S. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolline is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient of the patient application or patient. If you do not furnish the requested related to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may related that the patient process and/or examine your submission.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application port to public insepticines or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.